MedPath

Loratadine

Generic Name
Loratadine
Brand Names
Alavert, Alavert D, Allerclear, Claritin, Claritin-D, Diphen, Loradamed, Wal-itin, Wal-itin D
Drug Type
Small Molecule
Chemical Formula
C22H23ClN2O2
CAS Number
79794-75-5
Unique Ingredient Identifier
7AJO3BO7QN
Background

Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.

Indication

Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.

Associated Conditions
Allergic Dermatologic Disorders, Allergic Reaction, Allergic Rhinitis (AR), Allergy to Tree Pollen, Chronic Urticaria, Common Cold, Epiphora, Eye pruritus, Fever, Nasal Congestion, Nasal Itching, Pain, Perennial Allergic Rhinitis (PAR), Pruritus, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Sensation of burning in the eyes, Watery itchy eyes
Clinical Trials
Related News

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Phase 3
Completed
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Biological: Placebo
Biological: Short ragweed pollen allergen extract
Drug: Albuterol/Salbutamol
First Posted Date
2015-06-23
Last Posted Date
2019-09-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1025
Registration Number
NCT02478398

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Early Phase 1
Terminated
Conditions
Lymphoma
Interventions
Other: Placebo
Behavioral: Questionnaires
First Posted Date
2015-03-18
Last Posted Date
2019-04-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT02392039
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis

Phase 2
Completed
Conditions
Rhinitis, Allergic, Perennial
Interventions
Other: acupuncture combined moxibustion
First Posted Date
2015-01-15
Last Posted Date
2018-07-18
Lead Sponsor
Zhao Hong
Target Recruit Count
98
Registration Number
NCT02339714
Locations
🇨🇳

Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, Beijing, China

🇨🇳

Mentougou Hospital of TCM, Beijing, Beijing, China

🇨🇳

Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China

Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

Completed
Conditions
Leukemia
Lymphoma
Interventions
First Posted Date
2014-12-03
Last Posted Date
2018-07-03
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
61
Registration Number
NCT02305979
Locations
🇺🇸

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Patient Experience Study of Deoxycholic Acid Injection

Phase 3
Completed
Conditions
Moderate or Severe Submental Fullness
Interventions
Drug: Placebo
Other: Cold Compress
Other: Compression Chin Strap
First Posted Date
2013-12-10
Last Posted Date
2015-07-28
Lead Sponsor
Kythera Biopharmaceuticals
Target Recruit Count
84
Registration Number
NCT02007434
Locations
🇺🇸

Investigational Site, Tempe, Arizona, United States

NOLAN: Naproxen or Loratadine and Neulasta

Phase 2
Completed
Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
Biological: Pegfilgrastim
Drug: Chemotherapy
First Posted Date
2012-10-23
Last Posted Date
2018-01-30
Lead Sponsor
Amgen
Target Recruit Count
600
Registration Number
NCT01712009
Locations
🇺🇸

Research Site, Weston, Wisconsin, United States

A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)

First Posted Date
2011-11-10
Last Posted Date
2015-03-11
Lead Sponsor
Bayer
Target Recruit Count
255
Registration Number
NCT01469234

The Efficacy of Claritin in Healthy Subjects

Phase 4
Completed
Conditions
Healthy
Interventions
First Posted Date
2011-10-14
Last Posted Date
2018-03-13
Lead Sponsor
University of Chicago
Target Recruit Count
340
Registration Number
NCT01451996
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)

Phase 3
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
Drug: Placebo
First Posted Date
2011-08-10
Last Posted Date
2015-03-11
Lead Sponsor
Bayer
Target Recruit Count
575
Registration Number
NCT01413958

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

Phase 1
Terminated
Conditions
Rheumatoid Arthritis
Interventions
Biological: MK-8808
Biological: MabThera® (rituximab)
Biological: Rituxan® (rituximab)
First Posted Date
2011-07-11
Last Posted Date
2016-07-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
100
Registration Number
NCT01390441
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy